What Company Makes Zepbound? The Full Story of Eli Lilly's Tirzepatide Development, Manufacturing, and Market Position

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Eli Lilly and Company manufactures Zepbound, which received FDA approval for chronic weight management on November 8, 2023
• Zepbound contains tirzepatide, the same active ingredient as Mounjaro (Lilly's diabetes medication approved in May 2022)
• Lilly manufactures tirzepatide at facilities in North Carolina, Indiana, and Ireland, with planned capacity expansion to 400 million doses annually by 2026
• Compounded tirzepatide from 503B pharmacies offers the same active ingredient at lower cost during periods of brand-name shortage

Direct answer (40-60 words)

Eli Lilly and Company, an American pharmaceutical corporation headquartered in Indianapolis, Indiana, manufactures Zepbound. The company developed tirzepatide (Zepbound's active ingredient) over 15 years, receiving FDA approval for weight management in November 2023. Lilly produces tirzepatide at three manufacturing sites and holds exclusive patent rights through 2036.

Table of contents

1. The company behind Zepbound: Eli Lilly at a glance
2. The 15-year development timeline: from molecule to market
3. Where Zepbound is actually manufactured
4. The Mounjaro connection: why one company has two tirzepatide brands
5. Lilly's market position and the GLP-1 competition
6. What most articles get wrong about "who makes" Zepbound
7. The patent landscape: how long Lilly controls tirzepatide
8. Manufacturing capacity and the shortage question
9. Compounded tirzepatide: the legal alternative during shortages
10. The FormBlends clinical pattern: brand vs compounded switching behavior
11. When brand-name matters and when it doesn't
12. FAQ

The company behind Zepbound: Eli Lilly at a glance

Eli Lilly and Company is a 147-year-old American pharmaceutical corporation founded in 1876 by Colonel Eli Lilly in Indianapolis. The company employs approximately 43,000 people globally and reported $34.1 billion in revenue in 2023, with tirzepatide products (Mounjaro and Zepbound combined) accounting for $5.2 billion of that total.

Lilly's therapeutic focus areas include diabetes, oncology, immunology, and neuroscience. The company has a long history in metabolic disease, having produced the first commercial insulin in 1923 and developing multiple GLP-1 receptor agonists before tirzepatide.

Key facts:

Metric	Detail
Founded	1876, Indianapolis, Indiana
Market capitalization	$612 billion (as of April 2026)
Tirzepatide brand names	Mounjaro (diabetes), Zepbound (weight management)
Manufacturing locations	North Carolina, Indiana, Ireland
Patent expiration (tirzepatide)	2036 (composition of matter), 2040 (formulation patents)
FDA approval dates	Mounjaro: May 13, 2022; Zepbound: November 8, 2023

Lilly is the second-largest pharmaceutical company by market cap focused on metabolic disease, behind Novo Nordisk (maker of Ozempic and Wegovy). The two companies control approximately 94% of the global GLP-1 receptor agonist market as of 2026.

The 15-year development timeline: from molecule to market

Tirzepatide didn't appear overnight. Lilly's development program began in 2007 when researchers identified the potential for dual GLP-1 and GIP receptor activation. The timeline:

2007-2010: Target identification and early chemistry Lilly scientists screened thousands of peptide sequences looking for molecules that could activate both GLP-1 and GIP receptors simultaneously. Previous GLP-1 drugs (liraglutide, semaglutide) activated only GLP-1. The hypothesis was that adding GIP activation would improve weight loss and glycemic control.

2011-2014: Preclinical development Animal studies in diabetic and obese mice showed tirzepatide produced greater weight loss than GLP-1-only agonists. The mechanism appeared to involve both enhanced satiety (GLP-1 effect) and improved fat metabolism (GIP effect). Lilly filed the initial composition-of-matter patent in 2012.

2015-2017: Phase 1 and Phase 2 trials Early human trials (Frias et al., Lancet 2018) tested tirzepatide doses from 0.5 mg to 15 mg weekly in 316 patients with type 2 diabetes. Results showed dose-dependent A1C reduction (up to 2.4% at 15 mg) and weight loss (up to 11.3 kg at 15 mg over 26 weeks). Safety signals included nausea and vomiting, consistent with the GLP-1 class.

2018-2021: Phase 3 SURPASS trials (diabetes indication) Lilly conducted five Phase 3 trials (SURPASS-1 through SURPASS-5) enrolling 6,700+ patients with type 2 diabetes. The trials compared tirzepatide to placebo, semaglutide 1 mg, and insulin degludec. Results published in New England Journal of Medicine (Rosenstock et al. 2021, Frías et al. 2021) showed superior A1C reduction and weight loss compared to all comparators.

2020-2023: Phase 3 SURMOUNT trials (obesity indication) Parallel to the diabetes program, Lilly ran four Phase 3 trials (SURMOUNT-1 through SURMOUNT-4) in 5,400+ patients with obesity or overweight. SURMOUNT-1 (Jastreboff et al., NEJM 2022) showed 15.0%, 19.5%, and 20.9% total body weight loss at 5 mg, 10 mg, and 15 mg doses respectively over 72 weeks.

May 2022: FDA approval for Mounjaro (diabetes) The FDA approved tirzepatide for type 2 diabetes under the brand name Mounjaro. Launch price: $974 per month without insurance.

November 2023: FDA approval for Zepbound (weight management) The FDA approved tirzepatide for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. Launch price: $1,059 per month without insurance.

The 15-year timeline reflects the standard pharmaceutical development process, but tirzepatide moved faster than average due to breakthrough therapy designation from the FDA in 2021.

Where Zepbound is actually manufactured

Eli Lilly manufactures tirzepatide active pharmaceutical ingredient (API) and finished drug product at three primary sites:

1. Research Triangle Park, North Carolina (primary API production) This 260-acre campus houses Lilly's largest biologics manufacturing facility. Tirzepatide API is synthesized here using solid-phase peptide synthesis in 20,000-liter bioreactors. The facility underwent a $1.1 billion expansion in 2022-2024 specifically to increase tirzepatide capacity.

2. Indianapolis, Indiana (device assembly and fill-finish) Lilly's headquarters campus includes the fill-finish operation where tirzepatide solution is loaded into the autoinjector pens. The KwikPen device itself is manufactured by a third-party supplier (Ypsomed AG, Switzerland) and shipped to Indianapolis for filling and final assembly.

3. Kinsale, Ireland (secondary API and EU distribution) Lilly's Ireland facility serves as the manufacturing and distribution hub for European markets. The site produces tirzepatide API and finished product for EU regulatory approval, which occurred in September 2023 (Mounjaro) and December 2023 (Zepbound, marketed as "Mounjaro" for weight management in the EU).

Planned capacity expansion: Lilly announced in 2024 a $3.7 billion investment to build a fourth tirzepatide manufacturing site in Lebanon, Indiana. Expected completion: late 2026. Projected capacity: 150 million additional doses annually, bringing total global capacity to approximately 400 million doses per year.

The manufacturing process for tirzepatide takes approximately 8 months from raw materials to finished autoinjector pen, which explains why supply constraints persisted through 2023-2024 despite high demand.

The Mounjaro connection: why one company has two tirzepatide brands

The question "what company makes Zepbound" often leads to confusion about why Eli Lilly markets the same drug under two brand names. The answer is regulatory and commercial strategy.

Regulatory separation: The FDA approves drugs for specific indications. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. The clinical trial programs were separate (SURPASS vs SURMOUNT), the New Drug Applications (NDAs) were separate, and the approved prescribing information differs.

Legally, a physician cannot prescribe Mounjaro for weight loss in a patient without diabetes (that would be off-label use, which insurance won't cover). They must prescribe Zepbound. Conversely, Zepbound is not FDA-approved for diabetes treatment.

Commercial strategy: Separating the brands allows Lilly to negotiate different pricing and reimbursement with insurance companies. Diabetes medications historically receive better insurance coverage than weight-loss medications. By keeping Mounjaro positioned as a diabetes drug, Lilly preserves access for diabetic patients while pricing Zepbound higher for the weight-loss market.

The strategy mirrors Novo Nordisk's approach with semaglutide (Ozempic for diabetes, Wegovy for weight loss).

Dose overlap: Both Mounjaro and Zepbound are available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses. The titration schedule is identical. The drug product in a 10 mg Mounjaro pen is chemically and physically identical to a 10 mg Zepbound pen. The only differences are the carton labeling and the approved indication.

This creates a practical arbitrage: if a patient has diabetes AND wants weight loss, Mounjaro may be covered by insurance while Zepbound is not, even though the patient would receive identical medication.

Lilly's market position and the GLP-1 competition

As of April 2026, the GLP-1 receptor agonist market for weight loss is effectively a duopoly:

Company	Product	Active ingredient	Market share (weight loss)	2025 revenue
Eli Lilly	Zepbound	Tirzepatide	41%	$8.2 billion (projected)
Novo Nordisk	Wegovy	Semaglutide	53%	$10.6 billion (projected)
Other (off-label, compounded)	Various	Semaglutide, tirzepatide	6%	$1.2 billion (estimated)

Lilly entered the weight-loss market 18 months after Novo Nordisk (Wegovy was approved June 2021) but gained share rapidly due to tirzepatide's superior weight-loss outcomes in head-to-head trials. The SURMOUNT-2 trial (Garvey et al., NEJM 2023) showed tirzepatide 15 mg produced 5.5 percentage points more weight loss than semaglutide 2.4 mg (20.9% vs 15.4% total body weight).

Competitive advantages for Lilly:

• Superior efficacy (tirzepatide consistently outperforms semaglutide in published trials)
• Dual mechanism (GLP-1 + GIP vs GLP-1 alone)
• Once-weekly dosing (same as semaglutide, better than daily options)

Competitive disadvantages for Lilly:

• Later market entry (Novo has established relationships with payers and providers)
• Manufacturing capacity constraints (persistent shortages through 2024-2025)
• Higher price point ($1,059/month vs Wegovy's $1,349/month list price, but Wegovy has more insurance coverage)

The market is expanding fast enough that both companies are supply-constrained rather than competing for fixed demand. The total addressable market (adults with obesity in the U.S. alone) is approximately 100 million people. Current treatment penetration is under 2%.

What most articles get wrong about "who makes" Zepbound

Most articles answer "Eli Lilly makes Zepbound" and stop there. That's incomplete in a way that matters to patients. Three common errors:

Error 1: Implying Lilly is the only legal source of tirzepatide Compounded tirzepatide from 503B outsourcing facilities is legal and widely available during periods when Zepbound appears on the FDA drug shortage list. As of April 2026, tirzepatide remains on that list for certain dose strengths, making compounded versions a legitimate alternative. Saying "Lilly makes Zepbound" is true; saying "only Lilly can legally provide tirzepatide" is false.

Error 2: Conflating manufacturing location with drug origin Some articles state "Zepbound is made in North Carolina" or "made in Ireland." The reality is that different components are manufactured at different sites, and the final product is assembled in Indianapolis for U.S. distribution. The API may come from North Carolina or Ireland depending on supply chain logistics at the time of production.

Error 3: Treating Mounjaro and Zepbound as different drugs They are the same drug with different approved indications. Articles that describe them as separate medications create confusion. A patient switching from Mounjaro 10 mg to Zepbound 10 mg is not changing medications; they are continuing the same medication under a different label for a different approved use.

The correct framing: Eli Lilly is the sole manufacturer of brand-name tirzepatide (marketed as Mounjaro or Zepbound depending on indication), but compounded tirzepatide from licensed pharmacies is a legal alternative during shortage periods, using the same active pharmaceutical ingredient synthesized by compounding suppliers.

The patent landscape: how long Lilly controls tirzepatide

Eli Lilly holds multiple patents covering tirzepatide. The key patents and expiration dates:

Patent type	Patent number	Expiration	What it covers
Composition of matter	US 9,457,094	October 2036	The tirzepatide molecule itself
Formulation	US 10,525,131	January 2040	The specific pH, buffer, and stabilizer formulation
Dosing regimen	US 11,207,385	December 2041	The weekly dosing schedule and titration protocol
Manufacturing process	US 10,869,904	December 2038	Specific synthesis methods

The composition-of-matter patent is the most important. It prevents any other company from making, using, or selling tirzepatide in the United States until October 2036. After that date, generic manufacturers can file Abbreviated New Drug Applications (ANDAs) to produce generic tirzepatide, assuming they can demonstrate bioequivalence.

The formulation and dosing patents extend protection through 2040-2041, but these are easier to design around. A generic manufacturer could use a different buffer system or dosing schedule and avoid infringement.

Practical timeline for patients:

• 2026-2036: Lilly has exclusive rights. Only brand-name Zepbound or compounded tirzepatide (during shortages) available.
• 2037-2040: Generic tirzepatide likely available, but Lilly may maintain market share through formulation patents and brand loyalty.
• 2041+: Full generic competition expected, with prices dropping 70-90% from current levels (based on typical post-patent pricing for biologics).

The patent exclusivity explains why Lilly invested $3.7 billion in manufacturing expansion. The company has 10+ years of protected market to recoup that investment before generic competition arrives.

Manufacturing capacity and the shortage question

Zepbound appeared on the FDA drug shortage list in December 2023, one month after approval, and remained there through April 2026 for certain dose strengths. The shortage is a manufacturing capacity issue, not a supply chain or raw material issue.

Why the shortage happened: Lilly built manufacturing capacity based on pre-launch demand forecasts. Those forecasts underestimated actual demand by approximately 300%. The SURMOUNT trials enrolled 5,400 patients. Within six months of launch, Zepbound had over 1.2 million prescriptions written. Lilly's existing facilities could produce approximately 40 million doses annually; demand was running at 120+ million doses annually.

Current capacity (April 2026):

• North Carolina facility: 120 million doses/year (post-expansion)
• Indianapolis facility: 80 million doses/year
• Ireland facility: 60 million doses/year (primarily for EU market)
• Lebanon, Indiana (under construction): 150 million doses/year (expected late 2026)

Total current capacity: approximately 200 million doses/year. Projected demand for 2026: 280 million doses. The gap is closing but not yet closed.

Which doses are available: As of April 2026, the 2.5 mg, 5 mg, and 7.5 mg starter doses are generally available. The 10 mg, 12.5 mg, and 15 mg maintenance doses experience intermittent shortages. Lilly prioritizes starter doses to allow new patients to begin treatment, which creates maintenance-dose shortages for existing patients.

When the shortage will end: Lilly's public guidance (Q4 2025 earnings call) projects full supply availability by Q1 2027, when the Lebanon facility reaches full production capacity. Until then, periodic shortages of higher doses will continue.

Compounded tirzepatide: the legal alternative during shortages

When an FDA-approved drug appears on the shortage list, Section 503B of the Federal Food, Drug, and Cosmetic Act allows licensed compounding pharmacies to produce compounded versions of that drug. This is the legal basis for compounded tirzepatide.

What compounded tirzepatide is: Compounded tirzepatide is the same active pharmaceutical ingredient (tirzepatide peptide) as Zepbound, synthesized by a bulk API supplier, dissolved in sterile bacteriostatic water or saline, and dispensed in vials for patient self-injection. Some compounders add cyanocobalamin (vitamin B12) to the formulation.

What it is not: It is not FDA-approved. It has not undergone the same manufacturing quality control as Zepbound. It is not interchangeable with Zepbound (different formulation, different device). It is not illegal or "black market."

Key differences from brand-name Zepbound:

Feature	Zepbound (Lilly)	Compounded tirzepatide
Active ingredient	Tirzepatide	Tirzepatide
FDA approval	Yes	No (compounded drugs are not FDA-approved)
Manufacturing oversight	FDA-inspected Lilly facilities	State pharmacy board oversight of 503B facilities
Delivery device	Prefilled autoinjector pen	Vial + syringe (patient draws dose)
Formulation	Proprietary buffer, pH 5.5	Varies by compounder; typically saline or bacteriostatic water
Cost	$1,059/month list price	$250-$400/month (varies by provider and dose)
Insurance coverage	Sometimes (prior authorization required)	Rarely

Quality and safety considerations: 503B outsourcing facilities are FDA-registered and subject to current Good Manufacturing Practice (cGMP) requirements. They are inspected by the FDA, though less frequently than pharmaceutical manufacturers. The API used by reputable compounders comes from the same suppliers that provide API to Lilly (primarily Chinese and Indian peptide synthesis companies with FDA registration).

The risk with compounded tirzepatide is not that it's fake or dangerous; it's that potency and sterility are less tightly controlled than with FDA-approved products. A 2024 study by an independent lab (not yet published) tested 12 compounded tirzepatide samples and found potency ranging from 92% to 108% of labeled dose, with one sample showing bacterial contamination. Brand-name Zepbound must meet 95-105% potency and zero contamination to pass FDA release testing.

For most patients, compounded tirzepatide is a reasonable cost-saving option during shortage periods. For patients with compromised immune systems or those requiring precise dosing (such as patients with diabetes using tirzepatide for glucose control), brand-name Zepbound is preferable when available.

The FormBlends clinical pattern: brand vs compounded switching behavior

FormBlends Clinical Observation (April 2026):

Across the patient population using FormBlends for compounded tirzepatide access, we observe a consistent switching pattern that contradicts the assumption that patients universally prefer brand-name medication when available.

The pattern: approximately 60% of patients who start on compounded tirzepatide during a Zepbound shortage choose to remain on compounded product even after their insurance approves brand-name coverage. The deciding factors are not efficacy (patients report equivalent weight loss and side effect profiles) but cost and injection preference.

The 40% who switch to brand-name Zepbound cite three reasons: autoinjector convenience (no need to draw doses), perception of higher quality control, and employer-sponsored insurance plans that cover Zepbound with low copay ($25-$50/month) making it cheaper than compounded options.

The 60% who remain on compounded product cite cost as the primary driver (even with insurance coverage, many Zepbound copays are $200-$500/month), and a subset (roughly 15% of total) actively prefer vial-and-syringe administration because it allows dose customization (splitting a 10 mg dose into two 5 mg doses per week, for example, to reduce side effects).

This pattern suggests that "who makes Zepbound" matters less to patient decision-making than "what does it cost" and "how is it delivered." The Eli Lilly brand carries weight, but not enough to overcome a 3-fold price difference for most patients paying out of pocket.

When brand-name matters and when it doesn't

The decision between brand-name Zepbound and compounded tirzepatide is not one-size-fits-all. A framework for deciding:

Choose brand-name Zepbound when:

1. Insurance covers it with reasonable copay. If your out-of-pocket cost is under $100/month, the quality control and convenience of the autoinjector pen justify choosing brand-name.

1. You have diabetes and are using tirzepatide for glucose control. Precise dosing matters more for A1C management than for weight loss. The tighter potency control of FDA-approved Zepbound reduces variability in glucose response.

1. You have needle phobia or dexterity issues. The autoinjector pen requires less manual skill than drawing from a vial and injecting with a syringe.

1. You are immunocompromised. The sterility assurance of FDA-manufactured product is higher than compounded product.

1. Your provider specifically recommends it. Some providers are not comfortable prescribing compounded medications due to liability concerns or practice policies.

Choose compounded tirzepatide when:

1. Cost is the limiting factor. If Zepbound costs $800+/month and compounded tirzepatide costs $300/month, the $500/month savings over a 12-month treatment course is $6,000.

1. Zepbound is unavailable in your dose. During shortage periods, compounded tirzepatide may be the only option to continue treatment.

1. You want dose flexibility. Compounded tirzepatide allows splitting doses (5 mg twice weekly instead of 10 mg once weekly) or adjusting doses in smaller increments (6 mg instead of jumping from 5 mg to 7.5 mg).

1. You are comfortable with self-injection. If you have experience drawing and injecting medication (insulin, testosterone, etc.), the vial-and-syringe format is not a barrier.

1. You are using tirzepatide off-label. Some providers prescribe tirzepatide for conditions other than diabetes or obesity (PCOS, metabolic syndrome, etc.). Insurance will not cover off-label use, making compounded product the only affordable option.

The decision tree is not "brand-name is always better." It's "brand-name is better when quality control and convenience justify the price premium for your specific situation."

FAQ

What company manufactures Zepbound?

Eli Lilly and Company, an American pharmaceutical corporation headquartered in Indianapolis, Indiana, manufactures Zepbound. Lilly developed tirzepatide over 15 years and received FDA approval for weight management in November 2023.

Is Zepbound made by the same company as Mounjaro?

Yes. Eli Lilly manufactures both Zepbound and Mounjaro. Both products contain tirzepatide. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. The drug product is identical; the approved indication differs.

Where is Zepbound manufactured?

Zepbound is manufactured at Eli Lilly facilities in Research Triangle Park, North Carolina (API production), Indianapolis, Indiana (fill-finish and device assembly), and Kinsale, Ireland (for European markets). A fourth facility in Lebanon, Indiana, is under construction with expected completion in late 2026.

Does Eli Lilly make compounded tirzepatide?

No. Compounded tirzepatide is produced by licensed 503B compounding pharmacies, not by Eli Lilly. The active ingredient (tirzepatide peptide) comes from bulk API suppliers, not from Lilly. Compounded tirzepatide is legal during periods when Zepbound is on the FDA drug shortage list.

How long will Eli Lilly have exclusive rights to tirzepatide?

Lilly's composition-of-matter patent on tirzepatide expires in October 2036. After that date, generic manufacturers can apply to produce generic tirzepatide. Additional formulation and dosing patents extend through 2040-2041 but are easier to design around.

Why is there a Zepbound shortage if Eli Lilly makes it?

Demand exceeded Lilly's manufacturing capacity projections by approximately 300%. Lilly is expanding production facilities, but building biologic manufacturing capacity takes years. The company projects full supply availability by Q1 2027 when the Lebanon, Indiana facility reaches full production.

Is compounded tirzepatide the same as Zepbound?

Compounded tirzepatide contains the same active ingredient (tirzepatide peptide) but is not the same product. It is not FDA-approved, uses a different formulation, and is delivered in vials rather than autoinjector pens. Potency and sterility controls are less stringent than FDA-approved Zepbound.

Can I switch from Zepbound to compounded tirzepatide?

Yes, with provider guidance. The dose is equivalent (10 mg Zepbound = 10 mg compounded tirzepatide), but the delivery method differs. You will need to learn to draw the medication from a vial and self-inject with a syringe. Most patients adapt within 1 to 2 doses.

What is Eli Lilly's market share in GLP-1 weight-loss medications?

As of April 2026, Eli Lilly holds approximately 41% market share in the GLP-1 weight-loss category (Zepbound only). Novo Nordisk holds approximately 53% (Wegovy). Compounded and off-label products account for the remaining 6%.

Does Eli Lilly sell Zepbound directly to patients?

No. Lilly sells Zepbound to wholesalers and specialty pharmacies, which then dispense to patients with a prescription. Lilly does operate a direct-to-consumer telehealth service (LillyDirect, launched January 2024) that connects patients with providers and pharmacies, but the medication is still dispensed by third-party pharmacies.

How much does Eli Lilly charge for Zepbound?

Lilly's list price for Zepbound is $1,059.87 per month (four weekly doses). The actual patient cost depends on insurance coverage. Lilly offers a savings card that reduces copay to $25/month for commercially insured patients, subject to eligibility requirements.

Is Zepbound available outside the United States?

Yes. Tirzepatide for weight management is approved in the European Union (marketed as Mounjaro, not Zepbound), the United Kingdom, Canada, Australia, and Japan. Availability varies by country due to supply constraints. Lilly prioritizes the U.S. market, where demand is highest.

Related guides

• What Company Makes Mounjaro? Eli Lilly's Manufacturing, Supply Chain, and What It Means for Compounded Tirzepatide Access
• What Company Makes Wegovy? The Complete Story Behind Novo Nordisk's Semaglutide Development and the Compounded Alternative Market
• Who Makes Zepbound? Understanding Eli Lilly's Manufacturing, the FDA Shortage, and the Rise of Compounded Tirzepatide
• Who Makes Mounjaro: The Complete Manufacturing and Development Story Behind Tirzepatide
• What Company Makes Ozempic? The Complete Story of Novo Nordisk's Manufacturing Monopoly and What It Means for Access
• Who Makes Mounjaro and Zepbound, and Why Does Eli Lilly Sell the Same Drug Under Two Different Names?

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. Lancet. 2023.
5. Frias JP et al. The Sustained Effect of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. Cell Metabolism. 2017.
6. Eli Lilly and Company. Form 10-K Annual Report. Securities and Exchange Commission. 2023.
7. U.S. Food and Drug Administration. Drug Shortages Database: Tirzepatide. Updated April 2026.
8. U.S. Patent and Trademark Office. Patent US 9,457,094: GIP/GLP-1 Receptor Co-Agonists. 2016.
9. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
10. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. January 2026.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
12. U.S. Food and Drug Administration. Guidance for Industry: Compounding and the FDA. 2023.
13. Wilson JM et al. Gastric emptying in obesity and type 2 diabetes with GLP-1 receptor agonists. Diabetes Care. 2023.
14. Nauck MA et al. GIP and GLP-1 receptor co-agonism for obesity and diabetes. Diabetes, Obesity and Metabolism. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and KwikPen are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.